BMJ Open · 2014 · 96 citations · 31 references
Public HealthCardiologyEpidemiologic MethodsEpidemiologyRisk AssessmentCardiac Risk AssessmentCardiovascular DiseaseCardiovascular EpidemiologyCardiovascular RiskLiver DiseaseMortality AnalysisAtherosclerosis RiskAtherosclerotic ProgressionAtherosclerotic Risk AssessmentCardiovascular Disease MortalityCox RegressionFat Content MeasurementHepatic Steatosis AssessmentSteatosis Quantification
OBJECTIVE: We investigated if the differences in liver fat content would predict the development of non-fatal and fatal atherosclerotic endpoints (coronary heart disease and stroke). DESIGN, SETTING AND PARTICIPANTS: Our study group is a population-based, randomly recruited cohort (Oulu Project Elucidating Risk of Atherosclerosis, OPERA), initiated in 1991. The cohort consisted of 988 middle-aged Finnish participants. INTERVENTION: Total mortality and hospital events were followed up to 2009 based on the registry of the National Institute for Health and Welfare and the National death registry. MAIN OUTCOME MEASURE: The severity of hepatic steatosis was measured by ultrasound and divided into three groups (0-2). Cox regression analysis was used in the statistical analysis. RESULTS: In the follow-up of years 1991-2009, 13.5% of the participants with non-fatty liver, 24.2% of participants having moderate liver fat content and 29.2% of the participants having severe fatty liver experienced a cardiovascular event during the follow-up time (p<0.001). Severe liver fat content predicted the risk for future risk of cardiovascular event even when adjusted for age, gender and study group (HR 1.92, CI 1.32 to 2.80, p<0.01). When further adjustments for smoking, alcohol consumption, low-density lipoprotein-cholesterol, body mass index and systolic blood pressure were conducted, the risk still remained statistically significant (HR 1.74, CI 1.16 to 2.63, p<0.01). Statistical significance disappeared with further adjustment for QUICKI. CONCLUSIONS: Liver fat content increases the risk of future cardiovascular disease event in long-term follow-up but it is seems to be dependent on insulin sensitivity.
31
Heart Disease and Stroke Statistics—2011 Update
Véronique L. Roger, Alan S. Go, Donald M. Lloyd‐Jones et al. · Circulation · 2010 · 6.2K citations
Long‐term follow‐up of patients with NAFLD and elevated liver enzymes†‡
Mattias Ekstedt, Lennart Franzén, Ulrik Mathiesen et al. · Hepatology · 2006 · 2.3K citations
Lidia S. Szczepaniak, Pamela Nurenberg, David Léonard et al. · American Journal of Physiology-Endocrinology and Metabolism · 2004 · 1.6K citations
European cardiovascular disease statistics
Steven Allender, Peter Scarborough, Vito Peto et al. · Deakin Research Online (Deakin University) · 2008 · 1.5K citations